R D Gascoyne

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. pmc A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
    Daniel R Greenwald
    Stanford University, Stanford, CA, USA
    J Hematol Oncol 6:46. 2013
  2. pmc Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma
    David W Scott
    Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 31:692-700. 2013
  3. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
  4. pmc Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B)
    Derek Murphy
    Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Provincial Health Services Authority Laboratories, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
    Mol Cancer 9:14. 2010
  5. pmc Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas
    Minglong Zhou
    Centre for Translational and Applied Genomics CTAG, Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver Cancer Centre, BC V5Z 4E6, Canada
    Mol Cancer 7:12. 2008
  6. pmc Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma
    Johanna M Schuetz
    Canada s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
    BMC Med Genet 10:117. 2009
  7. ncbi request reprint Distinguishing between immunophenotype and genotype in non-Hodgkin's lymphomas
    Randy D Gascoyne
    Department of Pathology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    Curr Hematol Rep 2:443-4. 2003
  8. ncbi request reprint Emerging prognostic factors in diffuse large B cell lymphoma
    Randy D Gascoyne
    Department of Pathology and Laboratory Medicine, BC Cancer Agency and the University of British Columbia, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Curr Opin Oncol 16:436-41. 2004
  9. ncbi request reprint Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
    R D Gascoyne
    Departments of Pathology and Laboratory Medicine, Medical Oncology, and Epidemiology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Blood 93:3913-21. 1999
  10. doi request reprint Prognostic biomarkers in malignant lymphomas
    Randy D Gascoyne
    British Columbia Cancer Agency, Department of Pathology and Experimental Therapeutics, Vancouver, BC, Canada
    Leuk Lymphoma 51:11-9. 2010

Detail Information

Publications119 found, 100 shown here

  1. pmc A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
    Daniel R Greenwald
    Stanford University, Stanford, CA, USA
    J Hematol Oncol 6:46. 2013
    ..Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL. ..
  2. pmc Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma
    David W Scott
    Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 31:692-700. 2013
    ....
  3. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
    ..We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis...
  4. pmc Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B)
    Derek Murphy
    Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Provincial Health Services Authority Laboratories, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada
    Mol Cancer 9:14. 2010
    ....
  5. pmc Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas
    Minglong Zhou
    Centre for Translational and Applied Genomics CTAG, Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver Cancer Centre, BC V5Z 4E6, Canada
    Mol Cancer 7:12. 2008
    ..A disease-specific protein marker is yet to be identified in Hodgkin lymphoma cells. In order to define HL-specific biomarkers, novel murine monoclonal antibodies were developed in our laboratory...
  6. pmc Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma
    Johanna M Schuetz
    Canada s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
    BMC Med Genet 10:117. 2009
    ..The members of the MRE11-RAD50-NBS1 (MRN) complex and BLM have central roles in maintenance of DNA integrity. Severe mutations in any of these genes cause genetic disorders, some of which are characterized by increased risk of lymphoma...
  7. ncbi request reprint Distinguishing between immunophenotype and genotype in non-Hodgkin's lymphomas
    Randy D Gascoyne
    Department of Pathology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    Curr Hematol Rep 2:443-4. 2003
  8. ncbi request reprint Emerging prognostic factors in diffuse large B cell lymphoma
    Randy D Gascoyne
    Department of Pathology and Laboratory Medicine, BC Cancer Agency and the University of British Columbia, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Curr Opin Oncol 16:436-41. 2004
    ..The purpose of this review is to highlight recent advances in our understanding of novel biomarkers in DLBCL and how these might be incorporated into current risk-adjustment models for prognosis...
  9. ncbi request reprint Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
    R D Gascoyne
    Departments of Pathology and Laboratory Medicine, Medical Oncology, and Epidemiology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Blood 93:3913-21. 1999
    ..We conclude that ALCL is a heterogeneous disorder. However, ALK protein expression is an independent predictor of survival and serves as a useful biologic marker of a specific disease entity within the spectrum of ALCL...
  10. doi request reprint Prognostic biomarkers in malignant lymphomas
    Randy D Gascoyne
    British Columbia Cancer Agency, Department of Pathology and Experimental Therapeutics, Vancouver, BC, Canada
    Leuk Lymphoma 51:11-9. 2010
    ..This review focuses on recent advances in translational and clinical research on biomarkers in malignant lymphomas...
  11. ncbi request reprint Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma
    Randy D Gascoyne
    Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, 600 W 10th Avenue, Vancouver, BC V52 4E6 Canada
    Leuk Lymphoma 44:S13-20. 2003
    ..Recent data have shown that these very disparate translocations affect a common signaling mechanism, and thus unify all three under a common pathogenesis, resulting in the constitutive activation of the NF-kappaB pathway...
  12. doi request reprint Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
    D Villa
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Ann Oncol 21:1046-52. 2010
    ..We evaluated the risk of central nervous system (CNS) relapse in the R-CHOP in a population-based cohort of patients with DLBCL...
  13. ncbi request reprint Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience
    K J Savage
    University of British Columbia and the British Columbia Cancer Agency, Vancouver, BC, Canada
    Ann Oncol 17:123-30. 2006
    ..The optimal treatment is unknown, with some studies suggesting a superior outcome with dose-intensive chemotherapy regimens, and the role of radiotherapy remains ill-defined...
  14. ncbi request reprint A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency
    K M Ramadan
    Division of Hematology, British Columbia Cancer Agency, Vancouver, Canada
    Ann Oncol 18:129-35. 2007
    ..Primary bone lymphoma (PBL) is a distinct clinicopathological entity. Although PBL has been reviewed in several small studies, few reflect recent improvements in primary treatment...
  15. ncbi request reprint Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas
    S Knezevich
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Leukemia 19:659-63. 2005
    ..Molecular cytogenetic investigation is essential to identify cases of high-grade leukaemia/lymphoma with concurrent translocations affecting the BCL2 and MYC loci...
  16. pmc Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
    Nathalie A Johnson
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada
    Blood 113:3773-80. 2009
    ..CD20 and CD19 expression by FCM should be determined on all biopsies of patients with DLBCL because reduced CD20 expression cannot be reliably detected by IHC...
  17. pmc Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
    Nathalie A Johnson
    Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 114:2273-9. 2009
    ..A comprehensive cytogenetic analysis of BCL2 and MYC status on all aggressive lymphomas may identify a group of high-risk patients who may benefit from chemotherapeutic regimens that include rituximab and/or BCL2-targeted therapy...
  18. ncbi request reprint Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide
    R J Klasa
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Clin Cancer Res 6:2492-500. 2000
    ..These studies indicate that therapeutic strategies involving the use of an ASO targeting bcl-2 in combination with a cytotoxic agent may improve clinical outcomes...
  19. ncbi request reprint Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma
    Richard T Doocey
    Division of Hematology, Leukemia Bone Marrow Transplant Program of British Columbia, The Vancouver Hospital and Health Science Centre, Vancouver, BC, Canada
    Br J Haematol 131:223-30. 2005
    ..In conclusion, allo-SCT for relapsed or refractory aggressive histology NHL results in long-term EFS and OS of 40-50%. Patients with chemorefractory disease can have a durable remission post-transplant...
  20. pmc CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
    Nathalie A Johnson
    Clinical Professor of Pathology, Department of Pathology, British Columbia Cancer Agency, 600 W 10 Avenue, Vancouver, BC, V5Z 4E6, Canada
    Haematologica 94:423-7. 2009
    ..CD20 protein-negative relapses occur after R-CHOP therapy but their clinical relevance is unknown...
  21. ncbi request reprint Molecular heterogeneity of diffuse large B-cell lymphoma
    Randy D Gascoyne
    BC Cancer Agency, Vancouver, Canada
    Hematol J 5:S144-8. 2004
  22. doi request reprint Prognostic significance of secondary cytogenetic alterations in follicular lymphomas
    Nathalie A Johnson
    Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Genes Chromosomes Cancer 47:1038-48. 2008
    ..Consequently, studying clonal evolution in FL using serial biopsies may not represent the full complexity of genetic alterations leading to transformation...
  23. pmc Tumor-associated macrophages and survival in classic Hodgkin's lymphoma
    Christian Steidl
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
    N Engl J Med 362:875-85. 2010
    ..Current prognostic models predict the outcome of treatment with imperfect accuracy, and clinically relevant biomarkers have not been established to improve on the International Prognostic Score...
  24. doi request reprint Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma
    Mubarak Al-Mansour
    MSc, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, V5Z 4E6
    J Clin Oncol 28:793-9. 2010
    ..Because transformation can occur years after the primary diagnosis of NLPHL, long-term follow-up of these individuals is necessary to accurately estimate the risk of development of secondary DLBCL...
  25. doi request reprint Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
    David Hui
    Department of Medical Oncology, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
    Leuk Lymphoma 51:1658-67. 2010
    ..In patients with DLBCL treated with R-CHOP, the presence of extranodal disease remains prognostic, whereas a primary extranodal presentation did not affect outcome...
  26. doi request reprint BCL2 mutations in diffuse large B-cell lymphoma
    J M Schuetz
    Canada s Michael Smith Genome Sciences Center, BC Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
    Leukemia 26:1383-90. 2012
    ..DLBCL mutations were not independently associated with survival. Although previous studies of BCL2 mutations in FL have reported mutations to result in pseudo-negative BCL2 protein expression, we find this rare in de-novo DLBCL...
  27. ncbi request reprint Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18)
    D E Horsman
    Division of Pathology and Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada
    Genes Chromosomes Cancer 30:375-82. 2001
    ..Additional cytogenetic investigation is required to decipher the karyotypic complexity associated with the progression of follicular lymphoma...
  28. ncbi request reprint Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
    K J Savage
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    Ann Oncol 15:1467-75. 2004
    ....
  29. ncbi request reprint The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases
    Wing Y Au
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Leuk Lymphoma 45:519-28. 2004
    ..We conclude that the finding of an 8q24 aberration is of marked negative prognostic significance, either at diagnosis or at disease progression, in a variety of NHL...
  30. doi request reprint Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances
    K John J Cheung
    Center for Lymphoid Cancer, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada
    Blood 113:137-48. 2009
    ..Two of these 16 regions (1p36.22-p36.33 and 6q21-q24.3) were also predictors of transformation risk and independent of IPI. These prognostic features may be useful to identify high-risk patients as candidates for risk-adapted therapies...
  31. ncbi request reprint Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
    Pedro Farinha
    Department of Pathology, BC Cancer Agency, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada
    Blood 106:2169-74. 2005
    ..009 and P = .004, respectively). The LAM content of FL predicts survival, and these data support a prominent role for nonneoplastic immune cells in the biology of FL...
  32. ncbi request reprint Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes
    Ronald J de Leeuw
    Department of Cancer Genetics, British Columbia Cancer Agency, Vancouver, BC, Canada
    Hum Mol Genet 13:1827-37. 2004
    ..Further characterization of such minimally altered genomic regions identified using whole genome array CGH will define novel dominant oncogenes and tumor suppressor genes that play important roles in the pathogenesis of MCL...
  33. doi request reprint SNP analysis of minimally evolved t(14;18)(q32;q21)-positive follicular lymphomas reveals a common copy-neutral loss of heterozygosity pattern
    K J Cheung
    Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
    Cytogenet Genome Res 136:38-43. 2012
    ..The most frequent regions affected by cnLOH were 1p (17%), 6p (17%), 12q (13%) and 16p (13%). Our study suggests that cnLOH alterations may serve as important contributors to the pathological and clinical manifestations of FL...
  34. ncbi request reprint Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas
    W Y Au
    Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada
    Leuk Lymphoma 43:813-6. 2002
    ..The poor prognosis of t(14;19) disease is associated with the occurrence of recurrent secondary CG changes, commonly found in B cell lymphoproliferative diseases...
  35. doi request reprint Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results
    K M Ramadan
    Division of Hematology, Department of Medicine, Vancouver General Hospital and Health Sciences Centre, BC Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
    Bone Marrow Transplant 42:601-8. 2008
    ..Relapse and TRM remain significant problems in this setting, indicating the need for strategies whereby patients at high risk of transformation should be selected for early SCT, ideally before their actual transformation...
  36. ncbi request reprint Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes
    K W Song
    The Leukemia Bone Marrow Transplant Program of British Columbia, The Vancouver Hospital and Health Science Center, Division of Medical Oncology, British Columbia Cancer Agency and University of British Columbia, Canada
    Ann Oncol 18:535-40. 2007
    ..We conducted an intention-to-treat analysis of the strategy of SCT as definitive treatment of T-LBL...
  37. doi request reprint MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada V5Z4E6
    Blood 114:3533-7. 2009
    ..In the R-CHOP treatment era, MYC+ DLBCLs have an inferior prognosis. Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested...
  38. doi request reprint ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 111:5496-504. 2008
    ..Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course...
  39. ncbi request reprint Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis
    Janessa J Laskin
    Division of Medical Oncology, University of British Columbia and the British Columbia Cancer Agency, Vancouver, BC, Canada
    Leuk Lymphoma 46:1721-7. 2005
    ..Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse...
  40. ncbi request reprint High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hem
    Donna L Forrest
    Leukemia Bone Marrow Transplant Program of British Columbia, Canada
    J Clin Oncol 23:7994-8002. 2005
    ....
  41. ncbi request reprint Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma
    Kevin W Song
    Division of Hematology, Leukemia Bone Marrow Transplant Program of British Columbia, the Vancouver Hospital and Heath Science Centre, Vancouver, BC, Canada
    Br J Haematol 133:634-7. 2006
    ..In conclusion, approximately 50% of patients with chemosensitive BL who undergo SCT can be cured; however, a significant number of patients will not proceed to SCT because of early resistance or recurrence...
  42. ncbi request reprint CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma
    Kenneth S Wilson
    Department of Medical Oncology, Vancouver Island Centre, University of British Columbia, BC, Canada
    Leuk Lymphoma 48:1102-9. 2007
    ..The addition of rituximab to CHOP chemotherapy negates the adverse prognostic influence of BCL-2 protein expression on progression free and overall survival in DLBCL...
  43. doi request reprint Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma
    Abdulwahab J Al-Tourah
    Division of Medical Oncology, Fraser Valley and Vancouver Cancer Centers and the Department of Pathology and Biostatistics, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    J Clin Oncol 26:5165-9. 2008
    ..To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL)...
  44. doi request reprint Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size
    Belinda A Campbell
    Department of Radiation Oncology, Pathology, and Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    J Clin Oncol 26:5170-4. 2008
    ..Recent publications recommend a further reduction to involved-nodal radiation therapy (INRT), however, this has not been clinically validated...
  45. ncbi request reprint Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique
    Valia S Lestou
    Department of Pathology and Laboratory Medicine, BC Cancer Agency, Vancouver, British Columbia, Canada
    Genes Chromosomes Cancer 34:201-10. 2002
    ..Thus, the use of sophisticated multicolor molecular cytogenetic assays in the investigation of malignant lymphoma allows precise characterization of chromosomal alterations and will provide a better understanding of their biology...
  46. ncbi request reprint The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
    ..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials...
  47. doi request reprint High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes
    K John J Cheung
    Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
    Genes Chromosomes Cancer 49:669-81. 2010
    ....
  48. ncbi request reprint Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation
    Cynthia L Toze
    Division of Hematology, Leukemia BMT Program of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada
    Br J Haematol 127:311-21. 2004
    ..Allogeneic BMT has resulted in long-term disease-free survival for approximately 50% of this cohort of patients with advanced follicular lymphoma and most of them now enjoy robust health...
  49. ncbi request reprint Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes
    Douglas E Horsman
    Pathology and Laboratory Medicine Division, British Columbia Cancer Agency, Canada
    Br J Haematol 120:424-33. 2003
    ....
  50. ncbi request reprint High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver
    Julye C Lavoie
    Leukemia Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
    Blood 106:1473-8. 2005
    ..HD-ASCT can lead to durable remissions in relapsed or refractory HL with acceptable but definite late toxicity. The occurrence of late events necessitates lifelong medical surveillance...
  51. doi request reprint Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis
    K John J Cheung
    Center for Lymphoid Cancer, British Columbia Cancer Agency, Canada
    Cancer Res 70:9166-74. 2010
    ..06-9.57, P=0.039), respectively]. Our findings identify TNFRSF14 as a candidate gene associated with a subset of FL, based on frequent occurrence of acquired mutations and their correlation with inferior clinical outcomes...
  52. ncbi request reprint Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome
    Valia S Lestou
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
    Br J Haematol 122:745-59. 2003
    ....
  53. ncbi request reprint Molecular signatures of lymphoma
    Kerry J Savage
    Division of aMedical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Int J Hematol 80:401-9. 2004
    ..In this review, we have endeavored to include data from multiple investigator groups and tried to cover the breadth of lymphoid tumors, excluding acute and chronic leukemias...
  54. ncbi request reprint The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency
    Tamara N Shenkier
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 103:1008-17. 2005
    ..The objective of this study was to evaluate the clinical outcome of a population-based cohort of immunocompetent patients with primary central nervous system lymphoma (PCNSL) treated with 3 different strategies over 13 years...
  55. doi request reprint Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
    Christian Steidl
    Department of Pathology and Laboratory Medicine, Centre for Translational and Applied Genomics, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Blood 116:418-27. 2010
    ....
  56. ncbi request reprint Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency
    Tamara N Shenkier
    Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, Canada V5Z 4E6
    J Clin Oncol 20:197-204. 2002
    ..To evaluate clinical outcome of patients with limited-stage diffuse large-cell lymphoma (DLCL) treated with three cycles of chemotherapy followed by involved-region irradiation (IRRT)...
  57. ncbi request reprint Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
    Laurie H Sehn
    Division of Medical Oncology and Pathology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada V5Z 4E6
    J Clin Oncol 23:5027-33. 2005
    ..We conducted a population-based analysis to assess the impact of this combination therapy on adult patients with DLBCL in the province of British Columbia (BC)...
  58. ncbi request reprint Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis
    Valia S Lestou
    Department of Pathology, and Laboratory Medicine, British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6 Canada
    Genes Chromosomes Cancer 36:375-81. 2003
    ..3;q21.1-2) is a non-random event in NHL, suggesting a deletion-duplication mechanism involved in lymphoma progression and justifying further systematic research...
  59. doi request reprint The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation
    Pedro Farinha
    Pathology and Laboratory Medicine, BC Cancer Agency Center for Lymphoid Cancers, Vancouver, BC, Canada
    Blood 115:289-95. 2010
    ..008 and P < .001, respectively), while only FOXP3(+) pattern predicted RT (P = .004). We conclude that FOXP3(+) cell distribution significantly predicts survival and RT in FL...
  60. doi request reprint Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver Clinic, 600 W 10th Ave, Vancouver, British Columbia, Canada V5Z 4E6
    J Clin Oncol 29:1452-7. 2011
    ..We examined the significance of bone marrow involvement in patients treated in the current era of therapy including rituximab...
  61. doi request reprint Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy
    P Bains
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada
    Ann Oncol 24:428-32. 2013
    ..There is an inherent risk of transformation of follicular lymphoma to aggressive lymphoma; however, the frequency and impact on the outcome are unknown in limited-stage patients...
  62. ncbi request reprint Use of the polymerase chain reaction to detect B- and T-cell gene rearrangements in vitreous specimens from patients with intraocular lymphoma
    V A White
    Department of Pathology, Vancouver Hospital and Health Sciences Centre, British Columbia, Canada
    Arch Ophthalmol 117:761-5. 1999
    ..To determine whether the polymerase chain reaction for B- and T-cell gene rearrangements could be applied to vitreous specimens to aid in the diagnosis of intraocular lymphoma...
  63. ncbi request reprint Limited-stage mantle-cell lymphoma
    H A Leitch
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
    Ann Oncol 14:1555-61. 2003
    ..Mantle-cell lymphoma (MCL) is known to have a poor outcome, however, most patients present with advanced-stage disease. Little information is available on limited-stage MCL...
  64. ncbi request reprint Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1
    T Denyssevych
    Department of Advanced Therapeutics, Vancouver Cancer Centre, British Columbia Cancer Agency, and the University of British Columbia, Vancouver, BC, Canada
    Leukemia 16:276-83. 2002
    ..The unusual molecular features of the Tat-1 cell line render it a unique tool for studies focused on cytogenetic alterations, expression of multidrug resistance phenotype and expression of anti-apoptotic proteins in FL...
  65. doi request reprint Selective ablation of the YxxM motif of IL-7Ralpha suppresses lymphomagenesis but maintains lymphocyte development
    L C Osborne
    Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada
    Oncogene 29:3854-64. 2010
    ....
  66. doi request reprint Atypical lymphoid hyperplasia mimicking lymphoma
    David J Good
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
    Hematol Oncol Clin North Am 23:729-45. 2009
    ....
  67. doi request reprint Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma
    Carmen H Ng
    BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada
    Cancer Causes Control 21:11-22. 2010
    ..Plasma organochlorines have been implicated to increase the risk of non-Hodgkin lymphoma (NHL), and interaction with the aryl hydrocarbon receptor gene (AHR) may modify this risk...
  68. ncbi request reprint Organochlorines and risk of non-Hodgkin lymphoma
    John J Spinelli
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Int J Cancer 121:2767-75. 2007
    ..lowest quartile OR = 2.68, 95% confidence interval = 1.69-4.24). Our results provide further evidence that organochlorines contribute to NHL risk...
  69. ncbi request reprint Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma
    Catherine A Tucker
    The Department of Advanced Therapeutics, BC Cancer Research Center, 675 West 10th Avenue, 5th Floor, Vancouver, BC, Canada
    Leuk Res 30:449-57. 2006
    ..The results of the characterization of Z-138, HBL-2, NCEB-1 and JVM-2 reveal that this group of cell lines represents both classic and variant features of MCL...
  70. doi request reprint Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy
    Belinda A Campbell
    Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 116:3797-806. 2010
    ....
  71. ncbi request reprint Mantle cell lymphoma in the ocular adnexal region
    Audrey Looi
    Department of Ophthalmology and Visual Sciences, Vancouver General Hospital and University of British Columbia, Vancouver, Canada
    Ophthalmology 112:114-9. 2005
    ..To study the clinicopathologic features of mantle cell lymphoma (MCL) in the ocular adnexal region...
  72. ncbi request reprint Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21
    Laura Jane Henderson
    British Columbia Cancer Agency, Vancouver, BC, Canada
    Genes Chromosomes Cancer 40:60-5. 2004
    ..A BAC contig spanning a 6-Mb region has been anchored to the 6q16.2-q21 region. This map represents a useful resource for gene identification in this region, not only in lymphoma but also in other neoplasms with 6q alterations...
  73. ncbi request reprint Multicolor karyotyping and clinicopathological analysis of three intravascular lymphoma cases
    Haytham Khoury
    Leukemia BMT Program of British Columbia, Vancouver, British Columbia, Canada
    Mod Pathol 16:716-24. 2003
    ....
  74. ncbi request reprint Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes
    Ronald J DeLeeuw
    Department of Cancer Genetics, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
    Gastroenterology 132:1902-11. 2007
    ..Enteropathy-type T-cell lymphoma (ETL) is an aggressive extranodal T-cell non-Hodgkin lymphoma assumed to arise in the setting of celiac disease...
  75. ncbi request reprint Hodgkin's lymphoma in Chinese migrants to British Columbia: a 25-year survey
    W Y Au
    Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    Ann Oncol 15:626-30. 2004
    ..Compared with the West, Hodgkin's lymphoma in Oriental countries is characterized by a lower incidence rate and a higher proportion of mixed cellularity histology. Both environmental and genetic factors may be involved...
  76. doi request reprint Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy
    J Shustik
    Centre for Lymphoid Cancers, BC Cancer Agency, Vancouver, BritishColumbia, Canada
    Ann Oncol 22:1164-9. 2011
    ..Optimal therapy of FL grade 3 and its potential curability with anthracycline-based chemotherapy remain uncertain...
  77. ncbi request reprint Frequent occurrence of deletions in primary mediastinal B-cell lymphoma
    Lindsey R Kimm
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
    Genes Chromosomes Cancer 46:1090-7. 2007
    ..We conclude that consistent losses are present in the PMBCL genome. Given the similar frequency of losses to that of segmental gains of DNA, they are likely to play an important role in the pathogenesis of PMBCL...
  78. pmc Model-based clustering of array CGH data
    Sohrab P Shah
    Department of Computer Science, University of British Columbia, Vancouver, BC, Canada
    Bioinformatics 25:i30-8. 2009
    ..This can be due to the presence of heterogeneous cancer subtypes within a supposedly homogeneous population...
  79. ncbi request reprint Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma
    Pedro Farinha
    Department of Pathology, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada
    J Clin Oncol 23:6370-8. 2005
    ..It may be that the new MALT-related translocation involving the FOXP1 gene and other as yet undiscovered translocations may all have in common increased NF-kappaB signaling...
  80. pmc Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
    Ryan D Morin
    Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
    Nat Genet 42:181-5. 2010
    ..7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs. Our data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymatic activity in vitro...
  81. ncbi request reprint Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada
    John J Spinelli
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Int J Cancer 122:630-3. 2008
    ..The highest risks were associated with diffuse large B-cell lymphoma (OR = 7.3, 95%CI = 2.1-25.0) and marginal zone lymphoma (OR = 6.1, 95%CI = 1.1-33.9). Our results provide further evidence that HCV infection contributes to NHL risk...
  82. ncbi request reprint Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases
    Wing Y Au
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Leuk Lymphoma 43:783-91. 2002
    ..CG evolution in MCL follows a complex but defined pattern. Regions affected by recurrent changes are similar to other B cell lymphomas. The LN and PB groups of t(11;14)-associated LPD may have subtle differences in clonal evolution...
  83. pmc Impact of whole genome amplification on analysis of copy number variants
    T J Pugh
    Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
    Nucleic Acids Res 36:e80. 2008
    ....
  84. doi request reprint Classification of non-Hodgkin's lymphoma
    David J Good
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver Cancer Center, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Hematol Oncol Clin North Am 22:781-805, vii. 2008
    ..Helpful tables are included that outline the key diagnostic features...
  85. doi request reprint De novo transcriptome assembly with ABySS
    Inanc Birol
    Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada
    Bioinformatics 25:2872-7. 2009
    ..One can deduce gene expression levels using sequence coverage as a surrogate, identify coding changes or discover novel isoforms or transcripts. Especially for discovery of novel events, de novo assembly of transcriptomes is desirable...
  86. ncbi request reprint Cytogenetic findings in reactive lymphoid hyperplasia: significance of non-clonal t(3;14) and t(3;22)
    Wing Y Au
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Am J Hematol 70:133-8. 2002
    ..A clonal abnormality is highly predictive of concurrent and/or subsequent lymphoma. A lymphoma-specific but non-clonal abnormality does not necessarily herald the development of subsequent lymphoma...
  87. pmc Vascularization predicts overall survival and risk of transformation in follicular lymphoma
    Pedro Farinha
    Pathology, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, Canada
    Haematologica 95:2157-60. 2010
    ..05, P=0.001 and P=0.01, respectively) and IPI and TVD(90) predicted risk of transformation (P=0.008 and P=0.08, respectively). Increased angiogenesis is an independent marker of inferior survival and may promote transformation...
  88. doi request reprint Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment
    Christian Steidl
    Department of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Room 5 113, Vancouver, BC V5Z 1L3, Canada
    J Clin Oncol 29:1812-26. 2011
    ....
  89. ncbi request reprint Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Sandeep S Dave
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    N Engl J Med 351:2159-69. 2004
    ..We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival...
  90. ncbi request reprint Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma
    Marion P Butler
    Institute for Cancer Genetics, and the Department of Pathology, Columbia University, New York, NY 10032, USA
    Cancer Res 62:4089-94. 2002
    ..The identification of BCL-6 ABR provides new tools for the diagnosis of lymphomas carrying aberrations at 3q27 and deregulated BCL-6 genes...
  91. ncbi request reprint Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas
    Jose Ignacio Martin-Subero
    Institute of Human Genetics, University Hospital Schleswig Holstein Campus Kiel, Germany
    Genes Chromosomes Cancer 43:414-23. 2005
    ..Our findings imply that the two mechanisms resulting in MYC deregulation, that is, translocation and amplification, can occur simultaneously...
  92. pmc Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival
    Robin A Roberts
    Department of Pathology, University of Arizona, Tucson, AZ 85724 5043, USA
    Blood 108:311-8. 2006
    ..Although overall survival was better, survival of the lowest 10% of MHC II expressers was similarly poor in DLBCL and PMBCL. MHC II expression may define a therapeutic target in both these diseases...
  93. pmc BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma
    Javeed Iqbal
    Department of Pathology and Microbiology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE 68198 3135, USA
    Am J Pathol 165:159-66. 2004
    ..However, despite this higher proliferative activity, there was no significant difference in overall or failure-free survival between the t(14;18)-positive and -negative subsets within the GCB subgroup...
  94. ncbi request reprint Immunohistochemical investigation of SV40 large T antigen in Hodgkin and non-Hodgkin's lymphoma
    Pierre Brousset
    Department of Pathology, Purpan Hospital and INSERM U563 CPTP, CHU Purpan, Toulouse, France
    Int J Cancer 112:533-5. 2004
    ..Therefore, our results do not support the hypothesis that SV40 is implicated in the etiology of human lymphomas...
  95. doi request reprint Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma
    Marilu Nelson
    Human Genetics Laboratories, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Omaha, NE 68198 5440, USA
    Br J Haematol 141:461-9. 2008
    ..Although, genetic differences were noted in these subtypes, further studies are needed to determine the key pathogenetic events in PTCL...
  96. ncbi request reprint Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas
    Mattias Hoglund
    Department of Clinical Genetics, University of Lund, Sweden
    Genes Chromosomes Cancer 39:195-204. 2004
    ..The clinical implications of these pathways of clonal evolution need to be examined on a prospective basis in a large cohort of FLs...
  97. pmc Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    Andreas Rosenwald
    Metabolism Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Exp Med 198:851-62. 2003
    ..The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL...
  98. ncbi request reprint ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
    Randy D Gascoyne
    Department of Oncogeneiss and Signaling in Hematopoietic Cells, Instiut National de la Santé et de la Recherche Médicale U 563, Centre de Physiopatholgie de Toulouse Purpan, France
    Blood 102:2568-73. 2003
    ....
  99. ncbi request reprint MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma
    Dolors Sanchez-Izquierdo
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
    Blood 101:4539-46. 2003
    ..Together, these data implicate MALT1 as a dominant oncogene that may play a role in the pathogenesis of B-NHL...
  100. ncbi request reprint Molecular diagnosis of Burkitt's lymphoma
    Sandeep S Dave
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 354:2431-42. 2006
    ..We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma...
  101. pmc Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
    Silvia Bea
    Department of Pathology and Hematology Hospital Clinic, University of Barcelona, Spain
    Blood 106:3183-90. 2005
    ..In addition, gains involving the chromosomal region 3p11-p12 provided prognostic information that was statistically independent of the previously defined gene-expression-based survival model, thereby improving its predictive power...